From Labcorp's results release of 28 октября 2026 г.; its quarterly report has since been filed.
Revenue
Actual
3,81B $
+6,9 % y/y ↑ +2,1 % q/q ↑
Guided
—
No guide given
EPS, GAAP
Actual
3,22 $
+3,2 % y/y ↑ -12 % q/q ↓
Guided
—
No guide given
Operating income, GAAP
Actual
402,1M $
+1,4 % y/y ↑ -11 % q/q ↓
Guided
—
No guide given
Company outlook
Full year 2026
EPS, adjusted18,30 $ – 18,70 $↑Raised +1,0 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
Показать ещё 3
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
Кто покупает6
Physicians and medical practices order tests for patients and may receive the bills themselves or direct billing to patients or health plans.
Hospitals and health systems use Labcorp for testing, including outreach laboratory services and tests they send to an outside laboratory.
Health plans and managed care organizations pay for covered tests under negotiated fee schedules or per-member payment arrangements.
Показать ещё 3
Medicare and Medicaid pay for eligible tests under government fee schedules.
Patients pay for tests when uninsured, for their share of an insured test, or when they order tests directly.
Pharmaceutical, biotechnology, medical device and diagnostic companies, along with contract research organizations, buy laboratory services under contracts.
На чём держится и что может это сломать
От чего зависит бизнес
1Diagnostic revenue depends on reimbursement rules, coverage decisions and negotiated payment rates from health plans and government programs.
2A portion of diagnostic revenue depends on collecting patient balances, including deductibles, coinsurance and bills for uninsured patients.
3Biopharma Laboratory Services depends in part on research and development spending by pharmaceutical, biotechnology and medical device companies.
4Laboratory work depends on qualified staff, laboratory facilities, supplies and third-party transportation and services.
Что может пойти не так
1Changes to government or health-plan coverage and reimbursement, including changes affecting Medicaid or insurance exchanges, could reduce testing volumes or payments. The company has identified possible changes to Medicaid and the Affordable Care Act as a source of potential pressure on diagnostic testing.
2Patients account for a material portion of diagnostic receivables, and Labcorp may collect less than billed when patients cannot or will not pay their share.
3Reduced research and development spending, changes in pharmaceutical or medical-device regulation, or the loss or early termination of contracts could reduce demand for Biopharma Laboratory Services or leave Labcorp with contract costs it cannot recover.
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
Штаб-квартира
Burlington, North Carolina
Год основания
1978
Торгуется на
NYSE
Конец финансового года
December 31
Построено по собственной отчётности Labcorp Holdings Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
Keep exploring
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
Данные по 30 сентября 2026 г., из отчёта 10-Q, поданного 30 октября 2026 г.
Доходность за прошлые периоды
1W
+1,1 %
1M
+16,8 %
3M
+16,7 %
6M
+46,6 %
1Y
+40,3 %
5Y
+62,8 %
Labcorp sells medical testing to doctors, hospitals, health plans and patients, plus drug-development laboratory testing to pharmaceutical and biotechnology companies.
A
Grade A
Растёт уверенно→Стабильно
A
Становится ли бизнес крупнее и создаёт ли он настоящие деньги?
Сохраняется ли рост выручки или затухает?
Цена акции и оценка во времени
Полоса под ценой показывает оценку на каждую дату — только по отчётам, которые к тому моменту уже были опубликованы.
Действовавшая оценка:
ABCDF
Показано 2 из 41 кварталов истории оценок компании Labcorp Holdings Inc.. Остальные 39 уходят к октябрь 2016 г..
TMOThermo Fisher Scientific Inc.259,4B $A+
IDXXIdexx Laboratories Inc.55,5B $A+
IQVIQVIA Holdings Inc.43,7B $A
ILMNIllumina, Inc.31,3B $A+
DGXQuest Diagnostics Inc28,6B $A
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
